Alaithan Shaima, Naveen Nimbagal Raghavendra, Goudanavar Prakash S, Bhavani Penmetsa Durga, Ramesh Beveenahalli, Koppuravuri Naga Prashant, Fattepur Santosh, Sreeharsha Nagaraja, Nair Anroop B, Aldhubiab Bandar E, Shinu Pottathil, Almuqbil Rashed M
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagar 571448, Karnataka, India.
Pharmaceuticals (Basel). 2022 Aug 10;15(8):981. doi: 10.3390/ph15080981.
Currently, gastro-retentive dosage forms achieved a remarkable position among the oral drug delivery systems. This is a broadly used technique to hold the drug delivery systems for a long duration in the gastro intestine (GI) region, slow drug delivery, and overcome other challenges related to typical oral delivery such as low bioavailability. The current work aimed to formulate and characterize a new expandable gastro-retentive system through Itopride Hydrochloride (IH)’s unfolding process for controlled release. The IH-loaded unfolding film formulation was optimized using the Box-Behnken design for folding endurance and length of tested layer (LTL). Initially, the formulation was made using several anti-adhesive additives to promote the unfolding mechanism. Citric acid and sodium bicarbonate were selected as anti-adhesives based on these results. The enfolded film in a capsule shell was shown to unroll in the stomach fluids and render drug delivery up to 12 h in acidic conditions. A fabricated system should have dimensions more than the size of the relaxed pyloric sphincter, and as required, >20 mm LTL was identified. This further confirms that the residence period in the stomach is irrelevant to the fed or fasted condition. Based on desirability criteria, the formulation containing 143.83, 0.7982, and 14.6096 Eudragit L100, PEG, and sodium bicarbonate are selected as optimized formulations (O-IH-UF). The optimized formulation was further analyzed for various parameters such as tensile strength, mechanical strength, unfolding nature, degradability, and in vitro release studies. The pharmacokinetic study revealed greater AUC (area under the curve) and long half-life with the designed O-IH-UF formulation, confirming that the unfolding film type can be a favorable drug system for enhancing the bioavailability of low soluble drugs. The results showed that unfolding types of gastro retentive systems could potentiate the drugs with stability issues in an alkaline medium or those with absorption in acidic conditions.
目前,胃滞留剂型在口服给药系统中占据了显著地位。这是一种广泛应用的技术,可使药物递送系统在胃肠道(GI)区域长时间停留,实现药物缓慢释放,并克服与传统口服给药相关的其他挑战,如生物利用度低等问题。当前的工作旨在通过盐酸伊托必利(IH)的展开过程来制备和表征一种新型的可膨胀胃滞留系统,以实现控释。采用Box-Behnken设计对负载IH的展开膜制剂进行优化,考察折叠耐久性和测试层长度(LTL)。最初,使用多种抗粘添加剂来促进展开机制。基于这些结果,选择柠檬酸和碳酸氢钠作为抗粘剂。胶囊壳中的折叠膜在胃液中会展开,并在酸性条件下实现长达12小时的药物释放。制备的系统尺寸应大于松弛状态下幽门括约肌的尺寸,根据要求,确定LTL>20mm。这进一步证实了在胃中的停留时间与进食或禁食状态无关。基于合意性标准,选择含有143.83、0.7982和14.6096的Eudragit L100、聚乙二醇(PEG)和碳酸氢钠的制剂作为优化制剂(O-IH-UF)。对优化后的制剂进一步分析了各种参数,如拉伸强度、机械强度、展开性质、降解性和体外释放研究。药代动力学研究表明,设计的O-IH-UF制剂具有更大的曲线下面积(AUC)和更长的半衰期,证实展开膜类型可以成为提高低溶性药物生物利用度的良好药物系统。结果表明,胃滞留系统的展开类型可以增强在碱性介质中存在稳定性问题或在酸性条件下吸收的药物的效果。